Xcout IntelNeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.
Subscribe to see NeOnc Technologies Holdings, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
NeOnc Technologies Holdings, Inc. at a glance
NeOnc Technologies Holdings, Inc. is a biotechnology company headquartered in Calabasas, United States. It is publicly listed (NTHI) with a market capitalisation of $78.1M. Xcout tracks 36 named people at NeOnc Technologies Holdings, Inc., including Amir Farrokh Heshmatpour (President, Chief Executive Officer, Executive Chairman & Secretary).
NeOnc Technologies Holdings, Inc. leadership
- Amir Farrokh HeshmatpourPresident, Chief Executive Officer, Executive Chairman & Secretary
- AMIR HESHMATPOURCEO
- Thomas C. ChenCEO
- Keithly A. GarnettChief Financial Officer
- Josh Neman-EbrahimChief Clinical Officer
- David ChoiChief Accounting Officer
30 more named people on record for NeOnc Technologies Holdings, Inc., with roles, board committees and tenure — see the full roster →
NeOnc Technologies Holdings, Inc. funding rounds before its IPO
The most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $10M | — |
Financing after the IPO — public offerings and SEC Form D private placements — is not listed as a funding round.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
NeOnc Technologies Holdings, Inc. competitors
A few of NeOnc Technologies Holdings, Inc.'s closest competitors — see the full list of competitors and alternatives →
Neotx Holdings Ltd. is a biopharmaceutical company that develops cancer therapeutics and immunotherapies. It conducts clinical trials and researches proprietary technologies aimed at advancing cancer treatment.
Dome Therapeutics is a preclinical biotechnology company developing a nanomedicine designed to target brain cancer stem cells that survive standard glioblastoma treatments and drive tumor recurrence. Using a proprietary nanoparticle delivery platform, the company aims to cross the blood-brain barrier to deliver therapeutic payloads directly to these treatment-resistant cells.
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
Gibson Oncology is a biopharmaceutical company that develops treatments for brain cancer, focusing on its lead program involving the drug LMP744 for recurrent glioblastoma. The company is advancing LMP744 through clinical trials, including an NIH-conducted phase II trial for patients who have failed initial therapy.
TME Pharma is a clinical-stage biotechnology company that develops novel therapies targeting the tumor microenvironment to treat aggressive cancers such as glioblastoma and pancreatic cancer. Its proprietary technology neutralizes chemokines to break down tumor protection barriers, allowing combination treatments to achieve a greater therapeutic impact.
BrainChild Bio is a clinical-stage biotechnology company that develops CAR-T cell therapies to treat tumors in the central nervous system (CNS). The company prioritizes pediatric patients with brain tumors while also extending its technology platform to address adult indications such as glioblastoma and brain metastases.
Get NeOnc Technologies Holdings, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on NeOnc Technologies Holdings, Inc. in Xcout Intel
- 36 named people with titles, LinkedIn and board committees
- 2 funding rounds before the IPO with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access